<p><b>(A)</b> Immunization schedule of animals. Balb/c mice were inoculated with 100 μg of respective plasmids or 20 μg of proteins intradermally or with 2×10<sup>7</sup> PFU of recombinant MVA virus expressing gp120 and Gag-Pol-Nef of HIV clade B virus (MVA-B) via intraperitoneal route. The total Env-specific CD4<sup>+</sup><b>(B)</b> and CD8<sup>+</sup> (<b>C)</b> T-cell responses induced by the vaccination during adaptive and memory phases were measured by stimulating the splenocytes with overlapping peptides for gp120, as described in Materials and Methods. Data are representative of two independent experiments. * p < 0.05; ** p < 0.005; *** p < 0.001.</p
BACKGROUND: The immune parameters of HIV/AIDS vaccine candidates that might be relevant in protectio...
An effective vaccine against Human Immunodeficiency Virus (HIV) still remains the best solution to p...
Heterologous prime boost with DNA and recombinant modified vaccinia virus Ankara (rMVA) vaccines is ...
<p>(<b>A</b>) Description of the different vectors employed in the DNA/MVA immunization schemes appl...
<p>Δ <b>boosts.</b> (A) Schematic schedules of DNA prime/m8Δ-Env boost vaccination protocol. Mice we...
<p>(<b>A</b>) Vaccination schedule used. (<b>B</b>) Cumulative IFN-γ ELISPOT CD8<sup>+</sup> and CD4...
<p><b>A</b> & <b>B</b>) Balb/c mice were immunized i.m. at weeks 0 and 2 with 50 µg of pSG2-Ag85A or...
To enhance the eff iciency of DNA vaccines to HIV-1, we immunized BALB/c mice sequential ly with a g...
<div><p>In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF re...
<div><p>Prime-boost vaccination regimes have shown promise for obtaining protective immunity to HIV....
<p>BALB/c mice were immunized once with DNA encoding the indicated vaccine constructs. DNA (25 µg DN...
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinan...
<p><b>(A)</b> Mice (N = 5/group) were vaccinated 3 times (week 0, 3 and 6) with 20 µg of a plasmid e...
<p>For single-shot (A, B), BALB/c mice were immunized i.m. with 10<sup>6</sup> pfu rMVA) and splenic...
Prime-boost vaccination regimes have shown promise for obtaining protective immunity to HIV. Poorly ...
BACKGROUND: The immune parameters of HIV/AIDS vaccine candidates that might be relevant in protectio...
An effective vaccine against Human Immunodeficiency Virus (HIV) still remains the best solution to p...
Heterologous prime boost with DNA and recombinant modified vaccinia virus Ankara (rMVA) vaccines is ...
<p>(<b>A</b>) Description of the different vectors employed in the DNA/MVA immunization schemes appl...
<p>Δ <b>boosts.</b> (A) Schematic schedules of DNA prime/m8Δ-Env boost vaccination protocol. Mice we...
<p>(<b>A</b>) Vaccination schedule used. (<b>B</b>) Cumulative IFN-γ ELISPOT CD8<sup>+</sup> and CD4...
<p><b>A</b> & <b>B</b>) Balb/c mice were immunized i.m. at weeks 0 and 2 with 50 µg of pSG2-Ag85A or...
To enhance the eff iciency of DNA vaccines to HIV-1, we immunized BALB/c mice sequential ly with a g...
<div><p>In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF re...
<div><p>Prime-boost vaccination regimes have shown promise for obtaining protective immunity to HIV....
<p>BALB/c mice were immunized once with DNA encoding the indicated vaccine constructs. DNA (25 µg DN...
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinan...
<p><b>(A)</b> Mice (N = 5/group) were vaccinated 3 times (week 0, 3 and 6) with 20 µg of a plasmid e...
<p>For single-shot (A, B), BALB/c mice were immunized i.m. with 10<sup>6</sup> pfu rMVA) and splenic...
Prime-boost vaccination regimes have shown promise for obtaining protective immunity to HIV. Poorly ...
BACKGROUND: The immune parameters of HIV/AIDS vaccine candidates that might be relevant in protectio...
An effective vaccine against Human Immunodeficiency Virus (HIV) still remains the best solution to p...
Heterologous prime boost with DNA and recombinant modified vaccinia virus Ankara (rMVA) vaccines is ...